{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:31:10Z","timestamp":1781731870095,"version":"3.54.5"},"reference-count":33,"publisher":"Tsinghua University Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.26599\/1671-5411.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:25:31Z","timestamp":1724653531000},"page":"689-702","source":"Crossref","is-referenced-by-count":4,"title":["Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes"],"prefix":"10.26599","volume":"21","author":[{"name":"Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Nong","family":"JI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Dai","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","reference":[{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30313-3","author":"","unstructured":"","journal-title":"null"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"N Marx","year":"2023","unstructured":"N Marx. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. 2023, 44: 4043-4140.","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jamainternmed.2013.10074","article-title":"Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial","volume":"173","author":"M de Mulder","year":"2013","unstructured":"M de Mulder. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. 2013, 173: 1896-1904.","journal-title":"JAMA Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"G Rakipovski. The GLP-1 Analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways. 2018, 3: 844-857.","journal-title":"JACC Basic Transl Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","unstructured":"SP Marso. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. 2016, 375: 311-322.","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1111\/dom.14140","article-title":"Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials","volume":"22","author":"S Verma","year":"2020","unstructured":"S Verma. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. 2020, 22: 2193-2198.","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","unstructured":"SP Marso. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. 2016, 375: 1834-1844.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"HC Gerstein. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. 2019, 394: 121-130.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","unstructured":"B Zinman. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 2015, 373: 2117-2128.","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B Neal","year":"2017","unstructured":"B Neal. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. 2017, 377: 644-657.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"SD Wiviott. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 2019, 380: 347-357.","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","author":"","unstructured":"","journal-title":"null"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"JA Dormandy. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. 2005, 366: 1279-1289.","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"BM Scirica","year":"2013","unstructured":"BM Scirica. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. 2013, 369: 1317-1326.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"JB Green","year":"2015","unstructured":"JB Green. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 2015, 373: 232-242.","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"J Rosenstock. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. 2019, 321: 69-79.","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"J Rosenstock. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. 2019, 322: 1155-1166.","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"A Patel","year":"2008","unstructured":"A Patel. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. 2008, 358: 2560-2572.","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"HC Gerstein. Basal insulin and cardiovascular and other outcomes in dysglycemia. 2012, 367: 319-328.","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes","volume":"377","author":"SP Marso","year":"2017","unstructured":"SP Marso. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. 2017, 377: 723-732.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"RR Holman","year":"2017","unstructured":"RR Holman. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. 2017, 5: 877-886.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509255","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"MA Pfeffer. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. 2015, 373: 2247-2257.","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"RR Holman","year":"2017","unstructured":"RR Holman. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. 2017, 377: 1228-1239.","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"RE Pratley","year":"2018","unstructured":"RE Pratley. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. 2018, 6: 275-286.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/dom.12539","article-title":"Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"17","author":"A Ahmann","year":"2015","unstructured":"A Ahmann. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. 2015, 17: 1056-1064.","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/ALN.0000000000001515","article-title":"Perioperative hyperglycemia management: an update","volume":"126","author":"EW Duggan","year":"2017","unstructured":"EW Duggan. Perioperative hyperglycemia management: an update. 2017, 126: 547-560.","journal-title":"Anesthesiology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review","volume":"5","author":"MC Honigberg","year":"2020","unstructured":"MC Honigberg. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. 2020, 5: 1182-1190.","journal-title":"JAMA Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement","volume":"28","author":"A Liew","year":"2023","unstructured":"A Liew. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. 2023, 28: 415-424.","journal-title":"Nephrology (Carlton)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/jdi.13160","article-title":"Recommendations on the proper use of SGLT2 inhibitors","volume":"11","author":"on the Proper Use of SGLT2 Inhibitors Committee","year":"2020","unstructured":"on the Proper Use of SGLT2 Inhibitors Committee. Recommendations on the proper use of SGLT2 inhibitors. 2020, 11: 257-261.","journal-title":"J Diabetes Investig"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"C Mantsiou","year":"2020","unstructured":"C Mantsiou. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. 2020, 22: 1857-1868.","journal-title":"Diabetes Obes Metab"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"R Singh AKSingh","year":"2022","unstructured":"R Singh AKSingh. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. 2022, 14: 329-342.","journal-title":"World J Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"DR Riley","year":"2023","unstructured":"DR Riley. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. 2023, 25: 2897-2909.","journal-title":"Diabetes Obes Metab"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"AM Lincoff. Semaglutide and cardiovascular outcomes in obesity without diabetes. 2023, 389: 2221-2232.","journal-title":"N Engl J Med"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:25:34Z","timestamp":1724653534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2024.07.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2024.07.007","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}